Literature DB >> 347858

Bromocriptine treatment of hyperprolactinaemic hypogonadism.

M O Thorner, G M Besser.   

Abstract

Results of bromocriptine therapy of 70 women and 25 men with hyperprolactinaemia are reported together with those of 8 normoprolactinaemic and 3 post menopausal women. Galactorrhoea was present in 79% and 28% of the hyperprolactinaemic women and men respectively. 34 of the hyperprolactinaemic women had suspected pituitary tumours. Bromocriptine therapy resulted in lowering of prolactin levels to normal in 85 of the 95 patients, and in the remainder prolactin levels were lowered in all but one patient. Gonadal function was restored in all but seven of the hyperprolactinaemic women, and potency in all but 4 of the men. Normal cyclical function was restored or pregnancy was achieved in 5 of 6 normoprolactinaemic women with irregular cycles or amenorrhoea. Basal circulating LH and FSH levels and their responses to GnRH were normal or exaggerated in the majority of the women, but the LH responses to GnRH were impaired in 12 of 21 men. The results of 37 pregnancies in 31 women, 11 of whom had suspected pituitary tumours, are discussed together with the problems of possible tumour growth during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 347858

Source DB:  PubMed          Journal:  Acta Endocrinol Suppl (Copenh)        ISSN: 0300-9750


  12 in total

1.  Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.

Authors:  I Halperin; M D Rodriguez; C Cardenal; R Casamitjana; M J Martinez Osaba; V Lienas; E Vilardell
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

Review 2.  Therapeutic applications of bromocriptine in endocrine and neurological diseases.

Authors:  K Y Ho; M O Thorner
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Prolactin and growth hormone do not interfere with the response of mouse testes to hCG in vitro.

Authors:  A Bartke; S Dalterio
Journal:  Experientia       Date:  1982-05-15

4.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

5.  Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology.

Authors:  M Nissim; B Ambrosi; V Bernasconi; G Giannattasio; M A Giovanelli; M Bassetti; U Vaccari; P Moriondo; A Spada; P Travaglini; G Faglia
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

Review 6.  Bromocriptine in the treatment of hypogonadism and male impotence.

Authors:  C M March
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

7.  Mass screening for hyperprolactinemia and prolactinoma in men.

Authors:  A Miyake; M Ikegami; C F Chen; N Arita; T Aono; O Tanizawa; T Yoshikawa
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

8.  Morphologic effects of bromocriptine on spontaneously occurring pituitary prolactin-cell hyperplasia in old Long-Evans rats.

Authors:  D J McComb; P Hellmann; M O Thorner; D Scott; W S Evans; K Kovacs
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

9.  The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.

Authors:  R W Prescott; D G Johnston; P K Taylor; J Haigh; D R Weightman; K Hall; D B Cook
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

10.  Prolactin-secreting pituitary adenomas.

Authors:  M C Martin; E D Schriock; R B Jaffe
Journal:  West J Med       Date:  1983-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.